Revenue segments as reported by the company.

Water

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

General and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

IDEXX Laboratories

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IDEXX Labs reports robust Q4 performance, eyes international growth

IDEXX Laboratories delivered strong Q4 results with revenue and profit growth, driven by gains in key segments and customer retention.
While facing challenges from inflationary costs and international headwinds, the company aims for continued growth and market differentiation.
Opportunities lie in expanding organic revenue, focusing on international markets, and enhancing customer engagement for future success.

IDEXX reports robust Q1 performance, eyes pet oncology growth

IDEXX Laboratories delivered a strong Q1 performance with revenue and profit growth across segments.
The company's focus on innovation, cloud adoption, and pet oncology diagnostics positions it well for future growth.
Challenges include U.S. clinical vet visit trends and potential market share competition in lab modalities.
Opportunities lie in pet oncology diagnostics, cloud adoption, and international market growth for IDEXX.

IDEXX Laboratories excels in Q2, eyes pet healthcare trends

IDEXX Laboratories demonstrated robust growth in revenues and profitability, driven by strong performance in key segments.
While facing challenges in international markets and margin pressures, the company is poised to capitalize on pet healthcare trends.
Strategic initiatives like product launches and pricing adjustments position IDEXX well for sustained growth and market leadership.

IDEXX Laboratories excels in Q3 earnings amidst capacity challenges

IDEXX Laboratories demonstrated strong financial performance in Q3, driven by revenue growth and operational efficiency.
While facing challenges in clinical visit trends and capacity management, the company's strategic focus on innovation and market expansion positions it well for future growth.
Opportunities lie in addressing capacity constraints, expanding the sales force, and enhancing customer engagement through diagnostics testing.
Overall, IDEXX's commitment to providing integrated solutions and quality services underscores its resilience and potential for sustained success.

IDEXX Labs posts robust Q4 results, eyes growth through innovation

IDEXX Laboratories delivered strong financial performance in Q4 2023 and aims for continued growth in 2024.
The company's focus on innovation, customer feedback, and operational efficiency positions it well for future success.
Challenges include managing expenses, revenue diversification, and maintaining customer value perception.
Opportunities lie in organic revenue growth, margin improvement, and the launch of new diagnostic tests and platforms.

IDEXX Laboratories reports strong Q1 earnings and growth opportunities

IDEXX Laboratories delivered strong financial performance in Q1 2024, driven by solid organic revenue growth and profit gains.
The company remains committed to innovation, customer-centric solutions, and increasing standard of care in Companion Animal Healthcare.
Challenges in clinical visit growth levels and macro impacts on consumer demand are being addressed through operational focus and technology investments.
Opportunities for growth and improvement in software integration and diagnostic utilization dynamics present avenues for future success.

IDEXX Laboratories reports solid Q2 growth amidst sector challenges

IDEXX Laboratories navigated Q2 2024 with solid revenue growth and a focus on innovation and cost management. Despite challenges from sector trends and macroeconomic headwinds, the company remains optimistic about long-term growth prospects. Ongoing launches and a strong balance sheet position IDEXX well for future opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

IDEXX Laboratories has seen impressive revenue and margin growth in recent years. It's expanding its cloud presence, and is benefiting from the current pet-friendly environment.

IDEXX Laboratories: This Growth Name Is On Fire

HCA Healthcare

Eli Lilly

They're not the growth stocks you're probably used to being huge winners.

3 Surprising Stocks That Have Crushed the Market so Far This Year

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Here's How Much a $1000 Investment in Idexx Laboratories Made 10 Years Ago Would Be Worth Today

Goldman Sachs

Merck

Among the 32 stocks Goldman Sachs Group Inc. ( GS , Financial) finds attractive, six are in health care, including the highly diversified Mettler-Toledo International Inc. ( MTD , Financial), a name that might not be familiar to industry followers.

Goldman Sachs Names Merck, Mettler and IDEXX Attractive Health Care Stocks

Strong sales at the CAG and LPD arms are driving the top line for IDEXX Laboratories (IDXX).

IDEXX Laboratories (IDXX) Hits 52-Week High: What's Driving It?

The veterinary products company gained after an acquisition.

Why Idexx Laboratories Gained 13% in June

WESTBROOK, Maine, June 30, 2021 /PRNewswire/ --  IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has scheduled the release of its 2021 second quarter financial results for Friday, July 30, 2021 before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m.

IDEXX Laboratories to Release 2021 Second Quarter Financial Results

The stock price of IDEXX Laboratories, an animal healthcare company, has seen a rise of 12% in the last twenty-one trading days, while it is up a large 90% over the last one year. This rise can be attributed to the multiple positive developments for the company.

What's Next For IDEXX Stock After A 12% Rise In A Month?

Phibro Animal Health

PetIQ

Zoetis

Stocks like PetIQ (PETQ), IDEXX Laboratories (IDXX), Phibro Animal Health (PAHC) and Zoetis (ZTS) offering animal health products and services make great picks for long term.

Pandemic Boosts Animal Health Spending: 4 Stocks to Buy

AmerisourceBergen

Chewy

Covetrus Inc

Elanco Animal Health Inc

Freshpet

General Mills

Heska

Nestle SA

Proshares Pet Care ETF

Patterson Companies

J. M. Smucker

Unicharm Corp

Petco Health and Wellness

Zomedica

The physiological and psychological benefits that pets give us are meaningful. COVID has amplified our appreciation of this. Anticipating 6% annual growth until 2030 may be conservative, even across developed markets.

Overview Of Opportunities In Animal Companionship: A $200B Industry Growing At 6.1% Annually

The latest acquisition adds to IDEXX's (IDXX) cloud-based practice information management system (PIMS) segment.

IDEXX (IDXX) Acquires ezyVet to Boost Practice Management Arm

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?

Why Is Idexx (IDXX) Up 3.3% Since Last Earnings Report?

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider IDEXX (IDXX).

Why IDEXX (IDXX) Could Be an Impressive Growth Stock

Global leader in veterinary diagnostics and software enhances its practice management portfolio with acquisition of leading cloud-based solution WESTBROOK, Maine, June 2, 2021 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics and software, announced today the acquisition of ezyVet®, a fast-growing, innovative practice information management system (PIMS). With the acquisition, IDEXX further expands its world-class cloud software offerings that support customers with technology solutions that raise the standard of care for patients, improve practice efficiency, and enable more effective communication with pet owners.

IDEXX Acquires ezyVet

Idexx Labs reported another strong quarter and provided more details on its new product line.

This News Could Boost Idexx Labs' Earnings for Years to Come

Bruker

Inmode Ltd

Discovering new insights into Covid-19, particularly 'long Covid', InMode and Idexx peer Bruker continues to test new buy point. The post InMode, Idexx Peer Bruker Tests Buy Zone With New Insights Into 'Long Covid' appeared first on Investor's Business Daily.

InMode, Idexx Peer Bruker Tests Buy Zone With New Insights Into 'Long Covid'

WESTBROOK, Maine, May 26, 2021 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, will participate in the Stifel Virtual Jaws & Paws Conference on Wednesday, June 2, 2021. Jay Mazelsky, President and Chief Executive Officer, and Brian McKeon, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at 10:00 am (EDT).

IDEXX Laboratories to Present at Stifel Conference and Announces 2021 Virtual Investor Day

NVIDIA

After a 147% gain from its March 2020 lows, the BOUT ETF, featuring growth stocks like Nvidia and GS stock, tests turbulence. The post Breakout Watch: Nvidia, Idexx, GS Stock Among Growth Stocks Testing Turbulence appeared first on Investor's Business Daily.

Breakout Watch: Nvidia, Idexx, GS Stock Among Growth Stocks Testing Turbulence

IDEXX Laboratories, Inc. (IDXX) CEO Jay Mazelsky on Q1 2021 Results - Earnings Call Transcript

IDEXX (IDXX) registers strong contribution from its CAG business in the first quarter despite pandemic-induced challenges.

IDEXX (IDXX) Earnings Beat Estimates in Q1, '21 View Up

Idexx (IDXX) delivered earnings and revenue surprises of 36.63% and 5.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Idexx Laboratories (IDXX) Q1 Earnings and Revenues Surpass Estimates

In the latest trading session, Idexx Laboratories (IDXX) closed at $548.99, marking a -0.66% move from the previous day.

Idexx Laboratories (IDXX) Stock Moves -0.66%: What You Should Know

Joining fellow medical sector stock Veeva on this list of top long-term growth stocks, Idexx has investors wagging their tails ahead of Q1 earnings. The post After 240% Run, Long-Term Leader Sniffs Out New Breakout appeared first on Investor's Business Daily.

After 240% Run, Long-Term Leader Sniffs Out New Breakout

IDEXX (IDXX) first-quarter top line is expected to have benefited from strength in CAG and LPD businesses.

What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?

PayPal

This coming week may mark the last thrust up in this equity rally.

News for IDEXX Laboratories Stock (IDXX)